التفاصيل البيبلوغرافية
| العنوان: |
PS1141 PROTEOMICS MARKERS PROGNOSTIC FOR OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER TREATMENT; RESULTS FROM THE HOVON‐109 STUDY |
| المؤلفون: |
Hosnijeh, F. Saberi, Kater, A.P., van Oers, M.H., Posthuma, W.F., Chamuleau, M.E., Nijland, M., Doorduijn, J.K., Gelder, M., Hoogendoorn, M., De Croon, F., Wittebol, S., Kerst, M., Marijt, E.W., Raymakers, R.A., Koene, H.R., Schaafsma, M.R., Dobber, J.A., Tonino, S.H., Kersting, S.S., Langerak, A.W., Levin, M.‐D. |
| المصدر: |
HemaSphere ; volume 3, issue S1, page 517 ; ISSN 2572-9241 2572-9241 |
| بيانات النشر: |
Wiley |
| سنة النشر: |
2019 |
| المجموعة: |
Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: |
Background: Chronic lymphocytic leukemia (CLL) follows a highly variable clinical course. Predicting subsets of patients who will respond to a given therapy would improve health care efficacy. In recent years several molecular and cellular markers (chromosomal abnormalities including deletions and mutations, CD38, ZAP‐70, β2‐microglobulin, and IGHV mutational status) have been correlated with disease aggressiveness, and are partly being used for stratification of subjects into risk groups. Since many CLL cases show discordant prognostic factors, the identification of new parameters able to relate disease stage and clinical outcome is important to further improve treatment efficacy. Aims: To examine the prognostic ability of a) known proteomics markers measured pre‐treatment; with special interest in previously identified B‐cell activation markers (sCD23, sCD27, CXCL13), and b) to search for new proteomics markers that might be related to treatment response. Methods: Study subjects were treated in the HOVON‐109 clinical study (a phase I/II trial in 63 CLL patients designed for efficacy and safety of first‐line therapy involving chlorambucil, rituximab and lenalidomide). Total treatment duration was 12 months and all patients were followed until 5 years after registration. Fifty‐one eligible patients with an available sample at baseline were included in the current study. Serum samples were analyzed for 360 proteomics markers using a multiplex proximity extension assay (Olink Bioscience, Uppsala, Sweden). Kaplan‐Meier curves and Cox proportional hazards models were used for testing independent and additive effects of the markers for event‐free survival (EFS; time from registration to induction failure, progression or death from any cause, whichever comes first). Results: Thirty male and 21 female patients were included with mean age of 71 years. Median EFS was 23 months (26 events). Female and IGHV mutated patients showed longer EFS than male and unmutated patients. No significant survival effects were seen for ... |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1097/01.hs9.0000562848.09226.e8 |
| DOI: |
10.1097/01.HS9.0000562848.09226.e8 |
| الإتاحة: |
https://doi.org/10.1097/01.hs9.0000562848.09226.e8Test |
| حقوق: |
http://onlinelibrary.wiley.com/termsAndConditions#vorTest |
| رقم الانضمام: |
edsbas.E9861409 |
| قاعدة البيانات: |
BASE |
